Your browser doesn't support javascript.
loading
Pharmacotherapeutic follow-up in patients with type 1 diabetes in context of judicialization: possibility optimize costs
Oliveira, William Neves; Cazarim, Maurílio Souza; Mendonça, Thays Santos; Roque Obreli-Neto, Paulo; Pereira, Mariana Linhares; Baldoni, André Oliveira.
Afiliación
  • Oliveira, William Neves; Federal University of São João del-Rei. Divinópolis. BR
  • Cazarim, Maurílio Souza; Federal University of Juiz. Faculty of Pharmacy. Department of Pharmaceutical Sciences. Juiz de Fora. BR
  • Mendonça, Thays Santos; Federal University of São João del-Rei. Divinópolis. BR
  • Roque Obreli-Neto, Paulo; University Center of Integrated Colleges of Ourinhos. Pharmacy Department. Ourinhos. BR
  • Pereira, Mariana Linhares; Federal University of São João del-Rei. Pharmacy Course. Divinópolis. BR
  • Baldoni, André Oliveira; Federal University of São João del-Rei. Pharmacy Course. Divinópolis. BR
Braz. J. Pharm. Sci. (Online) ; 59: e23264, 2023. tab, graf
Article en En | LILACS | ID: biblio-1520318
Biblioteca responsable: BR40.1
Ubicación: BR40.1
ABSTRACT
Abstract In Brazil, insulin analogs stand out as one of the most demanded medications by judicial means. However, the guarantee of judicial access does not guarantee rational use. In context, pharmacotherapeutic follow-up (PF) is shown to be clinical effective strategy for patients with diabetes. To evaluate direct medical costs one year after performing PF in patients with type 1 diabetes mellitus using insulin analogs ordered by court in Public Health System (Sistema Único de Saúde - SUS). This is a partial economic analysis, nested within a quasi-experimental study. Patients with T1DM who receive insulin analogs by judicialization in a medium-sized Brazilian city participated. The PF was conducted following the method adapted from the Pharmacotherapy workup (PW). Data were collected considering the period of one year before the start of the intervention and one year after the start of the intervention. Direct medical costs were evaluated and the difference in costs was calculated. 28 patients participated in the intervention. After PF, direct costs were -$3,696.78. Sensitivity analysis showed that there is a 33.4 % chance for PF to present cost savings when compared to baseline. The PF has the potential to reduce direct medical costs from the perspective of the SUS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: LILACS Asunto principal: Pacientes / Diabetes Mellitus Tipo 1 / Judicialización de la Salud / Insulina Límite: Female / Humans / Male Idioma: En Revista: Braz. J. Pharm. Sci. (Online) Asunto de la revista: Farmacologia / Terapˆutica / Toxicologia Año: 2023 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Brasil

Texto completo: 1 Colección: 01-internacional Base de datos: LILACS Asunto principal: Pacientes / Diabetes Mellitus Tipo 1 / Judicialización de la Salud / Insulina Límite: Female / Humans / Male Idioma: En Revista: Braz. J. Pharm. Sci. (Online) Asunto de la revista: Farmacologia / Terapˆutica / Toxicologia Año: 2023 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Brasil